Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and an...

詳細記述

保存先:
書誌詳細
主要な著者: van Meerbeeck, J., Debruyne, C., van Zandwijk, N., Postmus, P. E., Pennucci, M. C., van Breukelen, F., Galdermans, D., Groen, H., Pinson, P., van Glabbeke, M., van Marck, E., Giaccone, G.
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 1996
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2074723/
https://ncbi.nlm.nih.gov/pubmed/8826866
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料